SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines

• Hauptverfasser: Thomas E. Hickey (VerfasserIn), Troy J. Kemp (VerfasserIn), Jimmie Bullock (VerfasserIn), Aaron Bouk (VerfasserIn), Jordan Metz (VerfasserIn), Abigail Neish (VerfasserIn), James Cherry (VerfasserIn), Douglas R. Lowy (VerfasserIn), Ligia A. Pinto (VerfasserIn)
• Format: Buch
• Veröffentlicht: Taylor & Francis Group, 2023-08-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Certain aspects of the immunogenicity and effectiveness of the messenger ribonucleic acid (mRNA) vaccines (mRNA-1273 and BNT162b2) developed in response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are still uncharacterized. Serum or plasma samples from healthy donor...